Zepbound® Online — See If You Qualify for Weight Management

A dual-hormone GLP-1/GIP medication built specifically for weight loss — evaluated and prescribed by a licensed provider, entirely online.

Start Your Free Visit

FDA-approved specifically for chronic weight management
Once-weekly injectable
Acts on two hormone receptors instead of one

Eligibility required. A licensed provider must evaluate your medical history before any prescription is written.

What Is Zepbound?

Zepbound is the brand name for tirzepatide dosed for weight management — it carries its own FDA approval for chronic weight loss in adults with obesity, or who are overweight with a weight-related condition, when combined with diet and exercise. It shares its active ingredient with Mounjaro, but Mounjaro's approval is limited to type 2 diabetes; Zepbound is the version built and approved specifically for weight loss.

What sets tirzepatide apart from single-hormone GLP-1 medications like semaglutide (Ozempic, Wegovy) is that it acts on two separate receptors — GLP-1 and GIP — rather than one. In head-to-head-style trial comparisons, this dual mechanism has been associated with somewhat greater average weight loss than semaglutide-based medications, though individual results vary widely and depend on dose, adherence, and lifestyle factors.

How Does Zepbound Work?

Tirzepatide mimics two hormones your gut releases naturally after eating: GLP-1 and GIP. Together, they slow how quickly your stomach empties and turn down appetite and cravings signaled to your brain — the combination behind sustained calorie reduction over time. Zepbound is typically dosed at a low starting level that increases gradually over several months, allowing your body to adjust before reaching a maintenance dose.

In a 72-week clinical trial of non-diabetic adults with obesity (or overweight plus a related condition), participants on the highest studied doses of tirzepatide lost substantially more weight on average, over a year of treatment paired with lifestyle changes, than those making diet and exercise changes alone. Most people see their fullest results around the one-year mark of consistent use.

Am I a Candidate for Zepbound?

A licensed provider makes the final call, but candidates typically:

Have a BMI of 30 or higher, or 27+ with a weight-related condition (such as high blood pressure, high cholesterol, or sleep apnea)
Don't have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2)
Aren't pregnant or planning pregnancy
Have discussed any history of pancreatitis, gallbladder disease, or severe gastrointestinal issues with their provider

If your primary concern is blood sugar rather than weight loss, your provider may instead evaluate you for Mounjaro, which shares Zepbound's active ingredient but is approved specifically for type 2 diabetes.

How Zealthy's Process Works

1. Complete your health intake.

A short online questionnaire covering your medical history, current medications, and goals.

2. Meet your provider.

A licensed clinician reviews your information and discusses whether Zepbound — or an alternative like Wegovy — fits your situation.

3. Receive your prescription, if appropriate.

Sent directly to your pharmacy of choice.

4. Stay supported.

Regular check-ins to monitor side effects, adjust dosing, and track progress.

Check My Eligibility

Cost and Insurance

Zepbound's list price without insurance typically runs over a thousand dollars a month, though coverage varies considerably by plan — some commercial insurers cover it for weight management with prior authorization, while others exclude GLP-1s for this use entirely. Eli Lilly offers a savings card that can significantly reduce costs for eligible patients paying cash. Zealthy's visit fee is billed separately from the medication itself, which your pharmacy charges based on your specific coverage.

Frequently Asked Questions

Important Safety Information

Zepbound is FDA-approved for chronic weight management in eligible adults with obesity, or overweight plus a weight-related condition, alongside diet and exercise. It carries a boxed warning for risk of thyroid C-cell tumors based on animal studies and should not be used by patients with a personal or family history of MTC or MEN 2. This page is informational and does not replace a one-on-one evaluation with a licensed healthcare provider.